| Dr Sandra Leticia Reis Crosara, MD | |
|
1000 4th St Sw, Mason City, IA 50401 | |
| (641) 428-6999 | |
| (641) 428-6678 |
| Full Name | Dr Sandra Leticia Reis Crosara |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 25 Years |
| Location | 1000 4th St Sw, Mason City, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922319656 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R9307 (Iowa) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | MD42153 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone North Iowa Medical Center | Mason city, IA | Hospital |
| Mitchell County Regional Health | Osage, IA | Hospital |
| Hansen Family Hospital | Iowa falls, IA | Hospital |
| Floyd County Medical Center | Charles city, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Iowa Mercy Clinics | 7810809076 | 242 |
News Archive
More than 10 per cent of weightlifters, in a study conducted by Southern Cross University in northern NSW, believe that they are too small, and may suffer from a psychological disorder known as muscle dysmorphia. Tthe psychological condition has been nicknamed as "reverse anorexia" or "manorexia." and is usually characterized by sufferers being determined to become more muscular, despite some exhibiting more muscles than the average person.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
"Republican lawmakers have long touted federal tort reform as way to bring down health-care costs. Democrats are coming around to the same position in response to what they've heard from constituents. ... President Barack Obama recently raised the issue as an olive branch to Republicans, directing the Department of Health and Human Services to spend $25 million to help states and health-care systems try alternative methods of resolving malpractice allegations."
› Verified 2 days ago
| Entity Name | North Iowa Mercy Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780278242 PECOS PAC ID: 7810809076 Enrollment ID: O20031105000273 |
News Archive
More than 10 per cent of weightlifters, in a study conducted by Southern Cross University in northern NSW, believe that they are too small, and may suffer from a psychological disorder known as muscle dysmorphia. Tthe psychological condition has been nicknamed as "reverse anorexia" or "manorexia." and is usually characterized by sufferers being determined to become more muscular, despite some exhibiting more muscles than the average person.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
"Republican lawmakers have long touted federal tort reform as way to bring down health-care costs. Democrats are coming around to the same position in response to what they've heard from constituents. ... President Barack Obama recently raised the issue as an olive branch to Republicans, directing the Department of Health and Human Services to spend $25 million to help states and health-care systems try alternative methods of resolving malpractice allegations."
› Verified 2 days ago
| Entity Name | Mason City Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043254055 PECOS PAC ID: 2860385572 Enrollment ID: O20040205001159 |
News Archive
More than 10 per cent of weightlifters, in a study conducted by Southern Cross University in northern NSW, believe that they are too small, and may suffer from a psychological disorder known as muscle dysmorphia. Tthe psychological condition has been nicknamed as "reverse anorexia" or "manorexia." and is usually characterized by sufferers being determined to become more muscular, despite some exhibiting more muscles than the average person.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
"Republican lawmakers have long touted federal tort reform as way to bring down health-care costs. Democrats are coming around to the same position in response to what they've heard from constituents. ... President Barack Obama recently raised the issue as an olive branch to Republicans, directing the Department of Health and Human Services to spend $25 million to help states and health-care systems try alternative methods of resolving malpractice allegations."
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sandra Leticia Reis Crosara, MD 621 S Illinois Ave Ste 103, Mason City, IA 50401-5489 Ph: (641) 428-3041 | Dr Sandra Leticia Reis Crosara, MD 1000 4th St Sw, Mason City, IA 50401 Ph: (641) 428-6999 |
News Archive
More than 10 per cent of weightlifters, in a study conducted by Southern Cross University in northern NSW, believe that they are too small, and may suffer from a psychological disorder known as muscle dysmorphia. Tthe psychological condition has been nicknamed as "reverse anorexia" or "manorexia." and is usually characterized by sufferers being determined to become more muscular, despite some exhibiting more muscles than the average person.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
"Republican lawmakers have long touted federal tort reform as way to bring down health-care costs. Democrats are coming around to the same position in response to what they've heard from constituents. ... President Barack Obama recently raised the issue as an olive branch to Republicans, directing the Department of Health and Human Services to spend $25 million to help states and health-care systems try alternative methods of resolving malpractice allegations."
› Verified 2 days ago
Burt Humburg, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-428-7000 Fax: 641-428-6383 | |
Sumathy Nagraj Iyengar, M.D., Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mercy Medical Center-hospitalist Dept, Mason City, IA 50401 Phone: 641-428-7000 | |
Mark C Johnson, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 910 N Eisenhower Ave, Mason City, IA 50401 Phone: 641-428-7799 Fax: 641-428-5274 | |
Dr. Joseph Dean Mccracken, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-428-6300 Fax: 641-428-6347 | |
Nathaniel Hitt, DO Infectious Disease Medicare: Medicare Enrolled Practice Location: 621 S Illinois Ave Ste 100, Mason City, IA 50401 Phone: 641-428-6900 Fax: 641-428-3909 | |
Dr. Byron T Beasley, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 250 S Crescent Dr, Mason City, IA 50401 Phone: 641-494-5300 Fax: 641-494-5329 | |
Radu Hagau, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 250 S Crescent Dr, Mason City, IA 50401 Phone: 641-494-5300 Fax: 641-494-5321 |